Ads
related to: sickle cell disease genes- Learn About Treatment
Learn About the Treatment Journey.
Watch the Video to Learn More.
- View Discussion Guides
Download Treatment Brochures,
Discussion Guides, and More.
- Safety and Side Effects
Review the Important Safety
Information & Side Effects.
- Patient FAQs
Get Answers to Common Questions.
Understand the Potential Risks.
- Find an ATC
Find an Authorized Treatment Center
On the Official Patient Website.
- Patient Information
View Important Patient Information.
Understand the Treatment.
- Learn About Treatment
Search results
Results From The WOW.Com Content Network
Some hemoglobinopathies (diseases of the blood) like Sickle Cell Anemia exist on a spectrum. Sickle Cell Anemia is an autosomal recessive, prototypical monogenic Mendelian disease, meaning that the disease follows Mendelian inheritance and is traced back to a single gene. Individuals with Sickle Cell Anemia present different severities of symptoms.
Genetic (X-linked recessive) [1] Risk factors: Triggered by infections, certain medication, stress, foods such as fava beans [1] [3] Diagnostic method: Based on symptoms, blood test, genetic testing [2] Differential diagnosis: Pyruvate kinase deficiency, hereditary spherocytosis, sickle cell anemia [2] Treatment
Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease. [1] [3] [4] [5]The most common side effects include stomatitis (mouth sores of the lips, mouth, and throat), low levels of platelets, white blood cells, and red blood cells, and febrile neutropenia (fever and low white blood cell count), consistent with ...
In the most common variant of sickle-cell disease, the 20th nucleotide of the gene for the beta chain of hemoglobin is altered from the codon GAG to GTG. Thus, the 6th amino acid glutamic acid is substituted by valine—notated as an "E6V" mutation—and the protein is sufficiently altered to cause the sickle-cell disease. [5]
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [1] [5] [2] It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.
Overdominance is a phenomenon in genetics where the phenotype of the heterozygote lies outside the phenotypical range of both homozygous parents. Overdominance can also be described as heterozygote advantage regulated by a single genomic locus, wherein heterozygous individuals have a higher fitness than homozygous individuals.
Ads
related to: sickle cell disease genes